Virologic Failure in First-Line Human Immunodeficiency Virus Therapy with a CCR5 Entry Inhibitor, Aplaviroc, plus a Fixed-Dose Combination of Lamivudine-Zidovudine: Nucleoside Reverse Transcriptase Inhibitor Resistance Regardless of Envelope Tropism

Ítems similars

• Virologic Failure in Therapy-Naïve Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope
  per: Kitrinos, Kathryn M., et al.
  Publicat: (2009)
• Centrosome Amplification Induced by the Antiretroviral Nucleoside Reverse Transcriptase Inhibitors Lamivudine, Stavudine and Didanosine
  per: Yu, Mia, et al.
  Publicat: (2009)
• Effect of HIV nucleoside reverse transcriptase inhibitor, Zidovudine, on the growth and differentiation of primary gingival epithelium
  per: Mitchell, Danielle, et al.
  Publicat: (2012)
• Effect of Lamivudine on the Plasma and Intracellular Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers
  per: Holdich, T., et al.
  Publicat: (2007)
• Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
  per: Borghetti, Alberto, et al.
  Publicat: (2021)